BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Clinical Research

Telix to Acquire QSAM Biosciences, Bolstering Bone Cancer Targeting

153Sm-DOTMP utilizes a cutting-edge chelating agent to deliver Samarium-153 radioisotope, offering potential advancements in bone cancer treatment....

February 08, 2024 | News

Nordic Bioscience Partners with Roche for PRO-C3 Biomarker in China

The PRO-C3 biomarker is relevant for drug development in particularly chronic diseases with a fibrotic component e.g., non-alcoholic steatohepatitis (NASH,...

February 06, 2024 | News

Novo Nordisk's Investment Arm, Novo Holdings, Seals $16.5 Billion Deal to Acquire Catalent in All-Cash Transaction

Catalent, Inc. (NYSE: CTLT), a prominent player in advancing global patient treatment solutions, and Novo Holdings, a holding and investment entity oversee...

February 06, 2024 | News

Sirius Therapeutics Begins Phase 1 Trial for Long-Acting Factor XI siRNA Anticoagulant

"This study is based on in vivo studies that have demonstrated a nearly 100% reduction in FXI levels for up to 6 months without bleeding events a...

February 04, 2024 | News

RemeGen Spotlights Three Major Advances in Global Cancer Battle, Closing Care Gap

Dr. Jianmin Fang, CEO of RemeGen, commented, "Cancer is the common enemy of mankind, and at RemeGen we feel a strong sense of responsibility and missi...

February 02, 2024 | News

SoniVie Completes Enrollment in REDUCED-1 Pilot Study for TIVUS™ Renal Denervation

SoniVie, an Israeli company developing a novel, proprietary Therapeutic Intra-Vascular Ultrasound (TIVUSTM) System to treat a variety of hypertensive disor...

February 01, 2024 | News

Endogenex Receives IDE Approval to Initiate Pivotal Clinical Study

Endogenex, Inc., a clinical stage medical device company dedicated to improving outcomes in patients with Type 2 Diabetes (T2D), announced that the U...

January 31, 2024 | News

WuXi XDC Partners with Multitude and HySlink for Accelerated ADC Discovery and Development

WuXi XDC will provide a fully integrated, one-stop bioconjugate platform and end-to-end CRDMO services. As WuXi XDC's strategic partner, Multitude Therapeu...

January 31, 2024 | News

Ractigen Therapeutics Partners with Utrecht Medical Center for saRNA Innovation in Neurodevelopmental Disorders

Professor Bobby Koeleman, Group Leader at the Department of Genetics within the Center for Molecular Medicine at Utrecht University, will le...

January 30, 2024 | News

Glenmark, Jiangsu Alphamab, and 3D Medicines Ink Global License Deal for Envafolimab (KN035)

Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East ...

January 26, 2024 | News

Ascletis Initiates Phase III Trial of ASC40 (Denifanstat) for Acne Treatment with First Patient Dosed

This Phase III clinical trial is a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and e...

January 25, 2024 | News

Metabolon and Sheffield Institute Partner for ALS Research and Biomarker Discovery

Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic developme...

January 24, 2024 | News

AIM ImmunoTech Initiates Phase 1b/2 Trial for Ampligen® and AstraZeneca's Imfinzi® in Late-Stage Pancreatic Cancer

AIM ImmunoTech Inc. announced that the first subject has been enrolled at Erasmus Medical Center in a Phase 1b/2 clinical trial combining AIM&rs...

January 23, 2024 | News

Merck's JAVELIN Bladder Regimen Shines in Real-World Data, Elevating Standard Care for Urothelial Carcinoma

Merck, a distinguished science and technology company, has announced groundbreaking real-world data that further solidify the JAVELIN Bladder regimen as a ...

January 23, 2024 | News

Stay Connected